Greater understanding of the heterogeneity of NSCLC has driven personalized approaches to patient management.2
of all NSCLC KRAS mutations in the US are KRAS G12C8
new patients with the KRAS G12C mutation are diagnosed with NSCLC in the US1,9
with NSCLC, comparable to the prevalence of all EGFR mutations1,10
ALK, anaplastic lymphoma kinase; BRAF, proto-oncogene B-Raf; EGFR, epidermal growth factor receptor; ERBB2, erb-B2 receptor tyrosine kinase 2; HER2, human epidermal growth factor receptor 2; KRAS, Kirsten rat sarcoma; MEK1, mitogen-activated protein kinase kinase 1; MET, mesenchymal-to-epithelial transition; MSI-H, microsatellite instability-high; NSCLC, non-small cell lung cancer; NTRK, neurotrophic tyrosine receptor kinase; NTRK1, neurotrophic tyrosine receptor kinase 1; PD-L1, programmed cell death ligand 1; PIK3CA, phosphoinositide 3-kinase, catalytic, alpha polypeptide; RET, rearranged during transfection; ROS1, c-ros oncogene 1; TMB, tumor mutational burden.
References: 1. Data on file, Amgen; 2020. 2. Pennell NA, et al. Am Soc Clin Oncol Educ Book. 2019;39:531-542. 3. Skoulidis F, et al. Nat Rev Cancer. 2019;19:495-509. 4. Pakkala S, et al. JCI Insight. 2018;3:e120858. 5. American Cancer Society. https://www.cancer.org/cancer/lung-cancer/about/what-is.html. Accessed October 12, 2020. 6. Duma N, et al. Mayo Clin Proc. 2019;94:1623-1640. 7. Gierman HJ, et al. J Clin Oncol. 2019;37:1585. 8. Arbour KC, et al. Clin Cancer Res. 2018;24:334-340. 9. American Cancer Society. https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html. Accessed October 12, 2020. 10. Ahmadzada T, et al. J Clin Med. 2018;7:153. 11. American Cancer Society. https://www.cancer.org/cancer/lung-cancer/treating-non-small-cell/targeted-therapies.html. Accessed October 12, 2020. 12. American Cancer Society. https://www.cancer.org/cancer/lung-cancer/treating-non-small-cell/immunotherapy.html. Accessed October 12, 2020. 13. Food and Drug Administration. https://www.fda.gov. Accessed October 12, 2020. 14. Lindeman NI, et al. J Thorac Oncol. 2018;13:323-358. 15. Aggarwal S, et al. Presented at: The European Society for Medical Oncology; September 2020; Virtual Congress. 16. Uras IZ, et al. Int J Mol Sci. 2020;21:4325. doi:10.3390/ijms21124325. 17. Kalemkerian GP, et al. J Clin Oncol. 2018;36:911-919. 18. Mosele F, et al. Ann Oncol. 2020;S0923-7534(20)39971-3. doi:10.1016/j.annonc.2020.07.014. 19. Gregg JP, et al. Transl Lung Cancer Res. 2019;8:286-301.